Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05182437 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Precision Radiation Treatment for Epilepsy (PRECISION)

Study acronym: PRECISION
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 1, 2023 to Dec 1, 2023 · Study sites: 3 to 1 · Eligibility criteria expanded, about 153 words · 2 morev2 Show 5 more changesShow less
    • Start date changed from estimate of Jan 1, 2023 to Dec 1, 2023
    • Study sites: 3 to 1
    • Eligibility criteria expanded, about 153 words
    • Study description expanded, about 8 words
    • Collaborators revised (4)

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The PRECISION-study offers a non-invasive, curative intervention for drug-resistant localised epilepsy patients who are not eligible for surgery. The intervention will consist of a single LINAC based SRT treatment and is given by the radiation-oncologist after detailed localisation of the epileptogenic zone with the neurologist, radiologist and neurosurgeon. This intervention will make curative-intent treatment possible where this could otherwise not be given and is a non-invasive and non-competitive alternative to epilepsy surgery. It is expected that the health costs for this curative treatment will not exceed standard treatment, such as lifelong medication and neuromodulation.
Trial Details
NCT Number NCT05182437
Lead Sponsor Maastricht Radiation Oncology
Collaborators: Maastricht University Medical Center, UMC Utrecht, Amsterdam University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Conditions Epilepsy
Enrollment 94 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov